Ariadne Bio Launches to Target Parkinson's Apathy With Non-Hallucinogenic Drug
- Ariadne Bio launched as a spinout of Palomar Labs, with lead program AB-300 — a clinical-stage-ready, non-hallucinogenic serotonin 2A (5-HT2A) receptor agonist.
- AB-300 targets apathy in Parkinson's disease, a symptom affecting a significant share of patients that currently has no approved treatment; evidence suggests SSRIs can worsen it.
- The company is funded by Palomar Labs and a grant from The Michael J. Fox Foundation for Parkinson's Research, supporting a Phase 1b trial of AB-300 planned for the second half of 2026.
- Ariadne is the second neuropsychiatry startup founded by Shlomi Raz, following Eleusis, whose lineage (via Beckley Psytech and AtaiBeckley) led to an Eli Lilly acquisition agreement in July 2026.
Ariadne is the latest entrant in the growing "psychedelic-like without the trip" race — biased 5-HT2A agonism is becoming the de-risking playbook that lets CNS developers chase serotonergic mechanisms while sidestepping hallucinogen stigma and REMS-heavy dosing; expect more spinouts to follow this template. Smarter still is the indication choice: apathy has zero approved therapies and SSRIs can actively worsen it, so AB-300 sidesteps the saturated Parkinson's motor-symptom field entirely — a genuine white-space bet rather than a me-too. Founder Shlomi Raz's Eleusis lineage (Beckley Psytech/AtaiBeckley → Lilly) is doing real work here too: it's a legible pattern for investors and future acquirers that this team can carry psychedelic-adjacent CNS assets to an exit. The Michael J. Fox Foundation grant alongside Palomar's funding also signals disease-foundation money increasingly co-underwriting rare/niche CNS bets alongside VC capital.
New startup to test psychedelic-like drug against Parkinson's symptom ↗